Nasdaq:US$9.61 (+0.03) | HKEX:HK$15.54 (-0.82) | AIM:£1.57 (+0.01)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer